Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00328380 | Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S. | PHASE3 | COMPLETED | 660 | — | — | Dec 1, 2005 | Sep 1, 2008 | Nov 25, 2019 | 3 | United States |
| NCT00742469 | Rifaximin for Prevention of Travellers' Diarrhea | PHASE3 | COMPLETED | 210 | — | — | Jun 1, 2005 | Apr 1, 2007 | Dec 18, 2019 | 1 | Mexico |
The efficacy of 14 days of rifaximin 600 mg once daily (QD) compared with placebo when taken by healthy subjects to prevent travelers' diarrhea (TD) resulting from all causes.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Rifaximin |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Rifaximin | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Subject is in good health (as determined by medical history) 2. Subject is planning on traveling anywhere outside the US (except Canada) for at least 5 and no more than 14 days 3. Subject is scheduled to depart on their planned trip no later than 14 days and no earlier than 4...